We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$123B
$40M 6.9%
+88,300
New +$38.1M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$30.5M 5.25%
+250,000
New +$28.7M
PRAX icon
3
PUT
Praxis Precision Medicines
PRAX
$8.77B
$29.7M 5.11%
100,600
+600
+0.6% +$112K
VKTX icon
4
CALL
Viking Therapeutics
VKTX
$4.31B
$24.2M 4.17%
688,900
+283,800
+70% +$10.1M
RNAM
5
CALL
DELISTED
Avidity Biosciences
RNAM
$23.7M 4.08%
328,000
+127,900
+64% +$8.26M
QQQ icon
6
PUT
Invesco QQQ Trust
QQQ
$466B
$18.4M 3.17%
+30,000
New +$18.4M
JAZZ icon
7
CALL
Jazz Pharmaceuticals
JAZZ
$15.5B
$17.9M 3.08%
105,300
+5,300
+5% +$813K
APGE icon
8
CALL
Apogee Therapeutics
APGE
$10.1B
$15.9M 2.74%
211,100
+83,700
+66% +$5.27M
BBIO icon
9
PUT
BridgeBio Pharma
BBIO
$15.9B
$15.3M 2.64%
+200,000
New +$13.1M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$14M 2.41%
345,880
+22,721
+7% +$525K
JNJ icon
11
Johnson & Johnson
JNJ
$609B
$13.8M 2.37%
+66,444
New +$13.1M
GPCR icon
12
CALL
Structure Therapeutics
GPCR
$3.45B
$13.3M 2.3%
+191,700
New +$7.83M
VKTX icon
13
Viking Therapeutics
VKTX
$4.31B
$11.9M 2.04%
336,849
+143,160
+74% +$5.07M
VKTX icon
14
PUT
Viking Therapeutics
VKTX
$4.31B
$11.1M 1.92%
+316,700
New +$11.2M
BBIO icon
15
CALL
BridgeBio Pharma
BBIO
$15.9B
$10.7M 1.84%
139,600
+8,200
+6% +$538K
JNJ icon
16
CALL
Johnson & Johnson
JNJ
$609B
$10.3M 1.78%
+50,000
New +$9.89M
ABVX
17
Abivax
ABVX
$11.9B
$10.2M 1.76%
75,644
+34,024
+82% +$3.71M
INCY icon
18
PUT
Incyte
INCY
$23.4B
$9.88M 1.7%
+100,000
New +$9.68M
INSM icon
19
CALL
Insmed
INSM
$23.5B
$9.19M 1.58%
+52,800
New +$9.63M
CAPR icon
20
CALL
Capricor Therapeutics
CAPR
$1.13B
$9.01M 1.55%
312,300
+12,300
+4% +$161K
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$11.5B
$8.7M 1.5%
146,361
-66,516
-31% -$3.62M
IONS icon
22
CALL
Ionis Pharmaceuticals
IONS
$8.99B
$8.4M 1.45%
106,200
+6,200
+6% +$467K
REGN icon
23
Regeneron Pharmaceuticals
REGN
$70.9B
$7.95M 1.37%
10,300
-19,860
-66% -$13.5M
INDV icon
24
CALL
Indivior Pharmaceuticals
INDV
$4.79B
$7.9M 1.36%
+220,300
New +$6.73M
QURE icon
25
PUT
uniQure
QURE
$2.77B
$7.22M 1.24%
301,800
+1,800
+0.6% +$69.5K
1
2 3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.